HK1161590A1 - Stem cell cultures - Google Patents

Stem cell cultures

Info

Publication number
HK1161590A1
HK1161590A1 HK12101691.6A HK12101691A HK1161590A1 HK 1161590 A1 HK1161590 A1 HK 1161590A1 HK 12101691 A HK12101691 A HK 12101691A HK 1161590 A1 HK1161590 A1 HK 1161590A1
Authority
HK
Hong Kong
Prior art keywords
stem cell
cell cultures
cultures
stem
cell
Prior art date
Application number
HK12101691.6A
Other languages
English (en)
Chinese (zh)
Inventor
Yue Xu
Sheng Ding
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of HK1161590A1 publication Critical patent/HK1161590A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
HK12101691.6A 2008-12-03 2012-02-21 Stem cell cultures HK1161590A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20080808P 2008-12-03 2008-12-03
PCT/US2009/066554 WO2010065721A1 (fr) 2008-12-03 2009-12-03 Cultures de cellules souches

Publications (1)

Publication Number Publication Date
HK1161590A1 true HK1161590A1 (en) 2012-07-27

Family

ID=42233609

Family Applications (3)

Application Number Title Priority Date Filing Date
HK12101691.6A HK1161590A1 (en) 2008-12-03 2012-02-21 Stem cell cultures
HK12102882.3A HK1162488A1 (en) 2008-12-03 2012-03-22 Stem cell cultures
HK16104657.8A HK1216883A1 (zh) 2008-12-03 2016-04-22 幹細胞培養

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK12102882.3A HK1162488A1 (en) 2008-12-03 2012-03-22 Stem cell cultures
HK16104657.8A HK1216883A1 (zh) 2008-12-03 2016-04-22 幹細胞培養

Country Status (15)

Country Link
US (7) US8691573B2 (fr)
EP (7) EP4296270A3 (fr)
JP (6) JP5793795B2 (fr)
KR (1) KR101551998B1 (fr)
CN (2) CN105001196B (fr)
AU (7) AU2009322346B2 (fr)
BR (2) BR122021005861B1 (fr)
CA (3) CA3128456A1 (fr)
ES (5) ES2489040T3 (fr)
HK (3) HK1161590A1 (fr)
IL (2) IL213205A (fr)
PT (1) PT3623374T (fr)
SG (2) SG196784A1 (fr)
WO (1) WO2010065721A1 (fr)
ZA (2) ZA201104019B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9896655B2 (en) 2008-12-03 2018-02-20 The Scripps Research Institute Methods of enhancing cell survival of stem cells

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2938049T3 (es) 2009-10-16 2023-04-04 Scripps Research Inst Inducción de células pluripotentes
JP2013519732A (ja) * 2010-02-17 2013-05-30 アムジエン・インコーポレーテツド 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体
KR20140063501A (ko) 2010-12-22 2014-05-27 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
DK3144319T3 (da) * 2011-09-22 2019-08-05 Ab Biolamina Cellekultursammensætning indeholdende laminin-521
ES2779152T3 (es) * 2013-10-07 2020-08-13 Kadmon Corporation Llc Derivados de (2-(5-isoindolin-2-il)pirimidin-4-il)-amina como inhibidores de Rho-quinasa para tratar enfermedades autoinmunes
SG10201807292YA (en) 2014-03-04 2018-09-27 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016123100A1 (fr) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Procédés et compositions pour induire la différenciation de cellules hématopoïétiques
US11441126B2 (en) 2015-10-16 2022-09-13 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
AU2016349504B2 (en) 2015-11-04 2023-02-09 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
AU2016348342B2 (en) 2015-11-04 2023-07-06 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2017127755A1 (fr) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions et procédés de modulation des cellules immunitaires en immunothérapies adoptives
US11203576B2 (en) 2016-03-11 2021-12-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
CN106632057B (zh) * 2016-08-23 2019-06-25 中国农业科学院兰州畜牧与兽药研究所 一种离子液体及利用其合成Thiazovivin的方法
JP7098615B2 (ja) 2016-12-05 2022-07-11 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
JP7477983B2 (ja) * 2020-02-12 2024-05-02 株式会社カネカ 細胞凝集抑制剤
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
EP4335847A1 (fr) * 2021-05-07 2024-03-13 Voronoi Inc. Dérivé hétéroaryle, son procédé de préparation et composition pharmaceutique le comprenant en tant que principe actif
WO2023233339A1 (fr) 2022-06-01 2023-12-07 Crispr Therapeutics Ag Compositions et procédés de différenciation de cellules souches en cellules nk
WO2023240248A2 (fr) 2022-06-09 2023-12-14 Umoja Biopharma, Inc. Compositions et méthodes pour différenciation de cellule nk
WO2024026391A1 (fr) 2022-07-27 2024-02-01 Umoja Biopharma, Inc. Différenciation de cellules souches en culture en suspension

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
EP0257275A3 (fr) * 1986-07-28 1990-05-23 American Cyanamid Company Dérivés de céphalosporine et de pénicilline
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5958792A (en) 1995-06-07 1999-09-28 Chiron Corporation Combinatorial libraries of substrate-bound cyclic organic compounds
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6185506B1 (en) 1996-01-26 2001-02-06 Tripos, Inc. Method for selecting an optimally diverse library of small molecules based on validated molecular structural descriptors
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
SE511957C2 (sv) 1996-12-06 1999-12-20 Ericsson Telefon Ab L M Broadcasting över ATM
US6399334B1 (en) 1997-09-24 2002-06-04 Invitrogen Corporation Normalized nucleic acid libraries and methods of production thereof
SI0928790T1 (en) * 1998-01-02 2003-06-30 F. Hoffmann-La Roche Ag Thiazole derivatives
EP2241541A1 (fr) 1998-01-05 2010-10-20 Neogenesis, Inc. Procédé d'identification d'un élément d'une bibliothèque combinatoire codée en masse
US6841347B1 (en) 1998-02-05 2005-01-11 The General Hospital Corporation In vivo construction of DNA libraries
US6541211B1 (en) 1998-05-20 2003-04-01 Selectide Corporation Apparatus and method for synthesizing combinational libraries
DE60024480T2 (de) * 1999-10-27 2006-07-27 Novartis Ag Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika
BR0109484A (pt) 2000-03-22 2004-06-29 Cellemetry Llc Método e aparelho para registrar a localização eletrônica de um dispositivo de comunicação celular móvel
WO2001090415A2 (fr) 2000-05-20 2001-11-29 The Regents Of The University Of Michigan Procede de production d'une bibliotheque d'adn utilisant l'amplification positionnelle
MXPA02011974A (es) * 2000-06-28 2004-09-06 Astrazeneca Ab Derivados de quinazolina sustituidos y su uso como inhibidores.
US6955879B2 (en) 2000-11-10 2005-10-18 Amicogen, Inc. Method for generating recombinant DNA library using unidirectional single-stranded DNA fragments
US20020132823A1 (en) 2001-01-17 2002-09-19 Jiahuai Han Assay method
ATE319703T1 (de) 2001-07-02 2006-03-15 Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
WO2004072068A1 (fr) * 2003-02-10 2004-08-26 Amgen Inc. Ligands du recepteur vanilloide et leur utilisation dans des traitements
EP2543376A1 (fr) * 2004-04-08 2013-01-09 Targegen, Inc. Inhibiteurs de benzotriazine de kinases
AU2006206611A1 (en) * 2005-01-19 2006-07-27 Bristol-Myers Squibb Company 2-phenoxy-N- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders
CN101155799A (zh) * 2005-03-16 2008-04-02 塔格根公司 嘧啶化合物和使用方法
AU2007227602A1 (en) 2006-03-16 2007-09-27 Novartis Ag Heterocyclic organic compounds for the treatment of in particular melanoma
WO2007123269A1 (fr) * 2006-04-19 2007-11-01 Astellas Pharma Inc. DÉRIVÉ d'azolecarboxamide
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
ZA200901914B (en) * 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
US8227605B2 (en) * 2006-10-31 2012-07-24 Schering Corporation 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
US20080182328A1 (en) * 2006-12-19 2008-07-31 The Burnham Institute Mammalian extraembryonic endoderm cells and methods of isolation
EP2368555B1 (fr) 2007-01-31 2016-04-20 Biosuccess Biotech Company Compositions et procédés d'utilisation de phorbolesters
US7838889B2 (en) 2007-08-10 2010-11-23 Eastman Kodak Company Solid-state area illumination system
CN101835764B (zh) * 2007-10-24 2012-09-19 安斯泰来制药有限公司 唑甲酰胺化合物或其盐
AU2009271019A1 (en) * 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
WO2010012793A1 (fr) * 2008-08-01 2010-02-04 Bayer Cropscience Sa Dérivés d'aminothiazole fongicides
WO2010065721A1 (fr) 2008-12-03 2010-06-10 The Scripps Research Institute Cultures de cellules souches
US8004201B2 (en) * 2009-03-06 2011-08-23 Himax Analogic, Inc. LED circuit
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9896655B2 (en) 2008-12-03 2018-02-20 The Scripps Research Institute Methods of enhancing cell survival of stem cells
US10351822B2 (en) 2008-12-03 2019-07-16 The Scripps Research Institute Methods of enhancing cell survival of stem cells
US10975352B2 (en) 2008-12-03 2021-04-13 The Scripps Research Institute Methods of enhancing cell survival of stem cells

Also Published As

Publication number Publication date
JP2016020347A (ja) 2016-02-04
KR101551998B1 (ko) 2015-09-09
US8691573B2 (en) 2014-04-08
ES2489040T3 (es) 2014-09-01
AU2015230747B2 (en) 2016-11-03
CN105001196B (zh) 2017-05-10
US20110224233A1 (en) 2011-09-15
JP2019043968A (ja) 2019-03-22
ES2971914T3 (es) 2024-06-10
EP4296270A2 (fr) 2023-12-27
AU2019210531B2 (en) 2021-04-01
AU2023251440A1 (en) 2023-11-09
CA2745266A1 (fr) 2010-06-10
SG171903A1 (en) 2011-07-28
CN102307882B (zh) 2015-06-10
JP6860544B2 (ja) 2021-04-14
JP2012510526A (ja) 2012-05-10
ES2898303T3 (es) 2022-03-07
JP2023073420A (ja) 2023-05-25
US10975352B2 (en) 2021-04-13
EP2370445A1 (fr) 2011-10-05
KR20110127119A (ko) 2011-11-24
US20140273214A1 (en) 2014-09-18
US20190352600A1 (en) 2019-11-21
EP3103804A1 (fr) 2016-12-14
BRPI0922345A2 (pt) 2015-08-11
HK1216883A1 (zh) 2016-12-09
EP3623374A1 (fr) 2020-03-18
JP2021095419A (ja) 2021-06-24
EP3936508A1 (fr) 2022-01-12
CA3128456A1 (fr) 2010-06-10
CA2745266C (fr) 2018-04-10
EP2370445A4 (fr) 2012-12-05
JP5793795B2 (ja) 2015-10-14
IL213205A0 (en) 2011-07-31
AU2015230747A1 (en) 2015-10-29
AU2009322346B2 (en) 2015-07-02
CA2995883A1 (fr) 2010-06-10
AU2017200667B2 (en) 2018-03-01
EP2789618B1 (fr) 2016-07-27
WO2010065721A1 (fr) 2010-06-10
EP3441394B1 (fr) 2020-01-29
US20160304833A1 (en) 2016-10-20
ES2779001T3 (es) 2020-08-13
CN102307882A (zh) 2012-01-04
AU2018203091A1 (en) 2018-05-17
US20210403862A1 (en) 2021-12-30
JP2017125061A (ja) 2017-07-20
BR122021005861B1 (pt) 2023-10-24
BRPI0922345B1 (pt) 2022-03-22
AU2019210531A1 (en) 2019-08-15
CA2995883C (fr) 2023-01-24
US10351822B2 (en) 2019-07-16
AU2021204635B2 (en) 2023-07-20
EP3103804B1 (fr) 2019-01-30
HK1162488A1 (en) 2012-08-31
AU2021204635A1 (en) 2021-07-29
EP3623374B1 (fr) 2021-09-08
ZA201104019B (en) 2012-11-28
EP2370445B1 (fr) 2014-07-23
ZA201206083B (en) 2014-04-30
US9340525B2 (en) 2016-05-17
EP4296270A3 (fr) 2024-01-03
JP6127092B2 (ja) 2017-05-10
EP2789618A1 (fr) 2014-10-15
AU2017200667A1 (en) 2017-03-02
SG196784A1 (en) 2014-02-13
IL228818A0 (en) 2013-12-31
EP3441394A1 (fr) 2019-02-13
AU2009322346A1 (en) 2011-06-30
ES2712074T3 (es) 2019-05-09
PT3623374T (pt) 2021-11-17
US9896655B2 (en) 2018-02-20
US8044201B2 (en) 2011-10-25
JP6476398B2 (ja) 2019-03-06
JP7256218B2 (ja) 2023-04-11
IL228818A (en) 2015-03-31
US20180127712A1 (en) 2018-05-10
IL213205A (en) 2014-11-30
EP3936508B1 (fr) 2023-12-06
US20110294761A1 (en) 2011-12-01
AU2018203091B2 (en) 2019-05-02
CN105001196A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
HK1216883A1 (zh) 幹細胞培養
HK1246827A1 (zh) 細胞培養方法
EP2315829A4 (fr) Cellules souches pluripotentes induites
GB2458863B (en) Improved culture of stem cells
SG10201500674YA (en) Pluripotent stem cells
EP2414510A4 (fr) Cellules souches pluripotentes induites
IL214798A0 (en) Methods and compositions for stem cell cultures
IL247310B (en) Mesenchymal stem cell differentiation
PL2046946T3 (pl) Hodowla pluripotencjalnych komórek macierzystych
ZA201000715B (en) Single pluripotent stem cell culture
GB0814249D0 (en) Uses of mesenchymal stem cells
ZA201202939B (en) Whole cell biocatalyst
EP2294182A4 (fr) Cultures de cellules souches multipotentes
EP2331676A4 (fr) Facteur de croissance d une cellule souche hématopoïétique
GB0919773D0 (en) Induced pluripotent stem cell
GB0818256D0 (en) stem cells
GB0901069D0 (en) Stem cell culture methods
GB0916476D0 (en) Stem cell culture methods
GB0918471D0 (en) Stem cells
GB0808778D0 (en) Cell culture technique
GB0922428D0 (en) Cell culture
GB0915268D0 (en) Cell culture